Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.9B | $766M | $241M | $509M | 3.3% | 3.7% | -10.8% |
| 2024 | $2.8B | $840M | $270M | $542M | 3.5% | 0.2% | -61.0% |
| 2023 | $2.8B | $714M | $693M | $10M | 8.8% | -16.9% | 21.8% |
| 2022 | $3.3B | $1.2B | $569M | $594M | 7.7% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 3,311.82 | 2,750.57 | 2,755.03 | 2,856.05 |
| Operating Revenue | - | 3,311.82 | 2,750.57 | 2,755.03 | 2,856.05 |
| Cost Of Revenue | - | 1,321.99 | 1,210.88 | 1,217.37 | 1,291.69 |
| Gross Profit | - | 1,989.83 | 1,539.69 | 1,537.66 | 1,564.36 |
| Operating Expense | - | 1,247.13 | 1,239.13 | 1,190.92 | 1,207.73 |
| Research And Development | - | 221.62 | 216.58 | 196.84 | 215.84 |
| Selling General And Administration | - | 1,025.51 | 1,022.55 | 994.07 | 991.89 |
| Total Expenses | - | 2,569.12 | 2,450.01 | 2,408.28 | 2,499.42 |
| Operating Income | - | 742.70 | 300.56 | 346.74 | 356.64 |
| Total Operating Income As Reported | - | 742.70 | 300.56 | 346.74 | 356.64 |
| EBITDA | - | 1,182.79 | 713.56 | 840.25 | 765.80 |
| Normalized EBITDA | - | 1,206.45 | 785.46 | 839.27 | 792.21 |
| EBIT | - | 755.79 | 281.79 | 412.40 | 360.46 |
| Interest Income | - | 3.59 | 72.13 | 73.19 | 31.10 |
| Interest Expense | - | 103.96 | 98.81 | 96.28 | 92.18 |
| Net Interest Income | - | -100.37 | -26.68 | -23.09 | -61.08 |
| Other Non Operating Income Expenses | - | 33.16 | -19.01 | -8.51 | -0.87 |
| Other Income Expense | - | 9.50 | -90.90 | -7.53 | -27.28 |
| Interest Income Non Operating | - | 3.59 | 72.13 | 73.19 | 31.10 |
| Interest Expense Non Operating | - | 103.96 | 98.81 | 96.28 | 92.18 |
| Net Non Operating Interest Income Expense | - | -100.37 | -26.68 | -23.09 | -61.08 |
| Pretax Income | - | 651.84 | 182.98 | 316.13 | 268.28 |
| Tax Provision | - | 139.16 | 3.47 | 33.06 | 28.39 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -5.05 | -1.37 | 0.10 | -2.80 |
| Net Income Continuous Operations | - | 512.68 | 179.50 | 283.07 | 239.88 |
| Net Income From Continuing And Discontinued Operation | - | 569.18 | 693.09 | 270.38 | 241.20 |
| Net Income From Continuing Operation Net Minority Interest | - | 512.68 | 179.50 | 283.07 | 239.88 |
| Net Income | - | 569.18 | 693.09 | 270.38 | 241.20 |
| Net Income Common Stockholders | - | 569.18 | 693.09 | 270.38 | 241.20 |
| Net Income Including Noncontrolling Interests | - | 569.18 | 693.09 | 270.38 | 241.20 |
| Normalized Income | - | 531.28 | 250.03 | 282.19 | 263.49 |
| Diluted NI Availto Com Stockholders | - | 569.18 | 693.09 | 270.38 | 241.20 |
| Basic Average Shares | - | 126.30 | 123.43 | 120.65 | 112.28 |
| Diluted Average Shares | - | 126.43 | 124.81 | 122.82 | 116.60 |
| Reconciled Depreciation | - | 427 | 431.77 | 427.85 | 405.34 |
| Reconciled Cost Of Revenue | - | 1,321.99 | 1,210.88 | 1,217.37 | 1,291.69 |
| Total Unusual Items | - | -23.65 | -71.90 | 0.98 | -26.40 |
| Total Unusual Items Excluding Goodwill | - | -23.65 | -71.90 | 0.98 | -26.40 |
| Net Income Discontinuous Operations | - | 56.50 | 513.59 | -12.69 | 1.32 |
| Special Income Charges | -16.43 | - | - | - | - |
| Restructuring And Mergern Acquisition | 16.43 | - | - | - | - |
| Gain On Sale Of Security | - | -23.65 | -71.90 | 0.98 | -26.40 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Revvity, Inc.this co. | RVTY | $11.4B | 47.36 | 1.58 | 3.3% | 18.15 |
| BrightSpring Health Services, Inc. | BTSG | $11.3B | 59.39 | 6.04 | 10.2% | 30.34 |
| Molina Healthcare, Inc. | MOH | $10.0B | 21.28 | 2.47 | 11.6% | - |
| Baxter International Inc. | BAX | $10.0B | -10.44 | 1.63 | -15.6% | 23.25 |
| Krystal Biotech, Inc. | KRYS | $9.1B | 44.30 |
| - |
| - |
| - |
| - |
| 7.44 |
| 16.8% |
| 51.16 |
| Charles River Laboratories International, Inc. | CRL | $8.9B | - | 2.83 | -4.6% | 27.52 |
| Henry Schein, Inc. | HSIC | $8.7B | 21.84 | 2.68 | 12.3% | 12.42 |
| Bio-Techne Corporation | TECH | $8.3B | 113.50 | 4.34 | 3.8% | 39.69 |
| Corcept Therapeutics Incorporated | CORT | $8.0B | 80.68 | 12.41 | 15.4% | 66.11 |
| Peer Median | - | 44.30 | 3.58 | 10.9% | 30.34 | |